Emerging trends in the stabilization of amorphous drugs

International Journal of Pharmaceutics

Volumn 453, Issue 1, 2013, Pages 65-79

  Laitinen, Riikka ^a   Lob̈mann, Korbinian ^a,b   Strachan, Clare J ^a,c   Grohganz, Holger ^b   Rades, Thomas ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Amorphous drug; Co amorphous; Dissolution; Mesoporous; Solubility; Stability

Indexed keywords

POLYMER; SILICON;

CHEMICAL STRUCTURE; CRYSTALLIZATION; DISPERSION; DRUG SOLUBILITY; DRUG STABILITY; ENTHALPY; ENTROPY; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 84884160394     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.04.066     Document Type: Review

References (120)

1. Aaltonen, J., Rades, T., 2009. Towards physico-relevant dissolution testing: the importance of solid-state analysis in dissolution. Dissol. Tech. 16, 47-54.
2. Ahuja, N., Katare, O.P., Singh, B., 2007. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur. J. Pharm. Biopharm. 65, 26-38. (Pubitemid 44827692)
3. Allesø, M., Chieng, N., Rehder, S., Rantanen, J., Rades, T., Aaltonen, J., 2009. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J. Control. Release 136, 45-53.
4. Ambike, A.A., Mahadik, K.R., Paradkar, A., 2005. Physico-chemical characterization and stability study of glassy simvastatin. Drug. Dev. Ind. Pharm. 31, 895-899. (Pubitemid 41540941)
5. Andronis, V., Zografi, G., 1997. Molecular mobility of supercooled amorphous indomethacin, determined by dynamic mechanical analysis. Pharm. Res. 14, 410-414. (Pubitemid 27204996)
6. Arora, K.A., Tayade, N.G., Suryanarayanan, R., 2011. Unintended water mediated cocrystal formation in carbamazepine and aspirin tablets. Mol. Pharm. 8, 982-989.
7. Baird, J.A., Van Eerdenbrugh, B., Taylor, L.S., 2010. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J. Pharm. Sci. 99, 3787-3806.
8. Bansal, S.S., Kaushal, A.M., Bansal, A.K., 2010. Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions. Drug. Dev. Ind. Pharm. 36, 1271-1280.
9. Bhattacharaya, S., Syrayanarayanan, R., 2009. Local mobility in amorphous pharmaceuticals - characterization and implications on stability. J. Pharm. Sci. 98, 2935-2953.
10. Bhugra, C., Pikal, M.J., 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci. 97, 1329-1349.
11. Bhugra, C., Shmeis, R., Pikal, M.J., 2008. Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin. J. Pharm. Sci. 97, 4446-4458.
12. Bladgen, N., de Matas, M., Gavan, P.T., York, P., 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59, 617-630. (Pubitemid 47285407)
13. Bøtker, J.P., Karmwar, P., Strachan, C.J., Cornett, C., Tian, F., Zujovic, Z., Rantanen, J., Rades, T., 2011. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions. Int. J. Pharm. 417, 112-119.
14. Chieng, N., Rades, T., Saville, D., 2008. Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryomilling. Eur. J. Pharm. Biopharm. 68, 771-780. (Pubitemid 351318218)
15. Chieng, N., Aaltonen, J., Saville, D., Rades, T., 2009. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur. J. Pharm. Biopharm. 71, 47-54.
16. Chiou, W.L., Riegelman, S., 1971. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60, 1281-1302.
17. Craig, D.Q.M., Royall, P.G., Kett, V.L., Hopton, M.L., 1999. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int. J. Pharm. 179, 179-207. (Pubitemid 29131430)
18. Descamps, M., Willart, J.F., Dudognon, E., Caron, V., 2007. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J. Pharm. Sci. 96, 1398-1407. (Pubitemid 46797497)
19. DiMartino, P., Palmieri, G.F., Martelli, S., 2000. Molecular mobility of the paracetamol amorphous form. Chem. Pharm. Bull. 8, 1105-1108. (Pubitemid 30660266)
20. Dranca, I., Bhattacharya, S., Vyazovkin, S., Suryanarayanan, R., 2009. Implications of global and local mobility in amorphous sucrose and trehalose as determined by differential scanning calorimetry. Pharm. Res. 26, 1064-1072.
21. Engers, D., Teng, J., Jimenez-Novoe, J., Gent, P., Hossack, S., Campbell, C., Thomson, J., Ivanisevic, I., Templeton, A., Byrn, S., Newman, A., 2010. A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. J. Pharm. Sci. 99, 3901-3922.
22. Etter, M.C., 1990. Encoding and decoding hydrogen bond patterns of organic compounds. Acc. Chem. Res. 23, 120-126.
23. Fukuoka, E., Makita, M., Yamamura, S., 1989. Glassy state of pharmaceuticals III: thermal properties and stability of glassy pharmaceuticals and their binary glass systems. Chem. Pharm. Bull. 37, 1047-1050. (Pubitemid 19144144)
24. Graeser, K.A., Patterson, J.E., Rades, T., 2009a. Applying thermodynamic and kinetic parameters to predict the physical stability of two differently prepared amorphous forms of simvastatin. Curr. Drug Deliv. 6, 374-382.
25. Graeser, K.A., Patterson, J.E., Zeitler, J.A., Gordon, K.C., Rades, T., 2009b. Correlating thermodynamic and kinetic parameters with amorphous stability. Eur. J. Pharm. Sci. 37 (492), 498.
26. Grzybowska, K., Paluch, M., Grzybowski, A., Wojnarowska, Z., Hawelek, L., Kolodziejczyk, K., Ngai, K.L., 2010. Molecular dynamics and physical stability of amorphous anti-inflammatory drug: celecoxib. J. Phys. Chem. B 114, 12792-12801.
27. Hailu, S.A., Bogner, R.H., 2011. Complex effects of drug/silicate ratio. Solid-state equivalent pH and moisture on chemical stability of amorphous quinapril hydrochloride coground with silicates. J. Pharm. Sci. 100, 1503-1515.
28. Hancock, B.C., Parks, M., 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17, 397-404. (Pubitemid 30395293)
29. Hancock, B.C., Shamblin, S.L., 2001. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim. Acta 380, 95-107. (Pubitemid 33096427)
30. Hancock, B.C., Zografi, G., 1994. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm. Res. 11, 471-477. (Pubitemid 24144434)
31. Hancock, B.C., Zografi, G., 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86, 1-12.
32. Hancock, B.C., Shamblin, S.L., Zografi, G., 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12, 799-806.
33. Hancock, B.C., Shalaev, E.Y., Shamblin, S.L., 2002. Polyamorphism: a pharmaceutical science perspective. J. Pharm. Pharmacol. 54, 1151-1152.
34. Hoppu, P., Jouppila, K., Rantanen, J., Schantz, S., Juppo, A.M., 2007. Characterisation of blends of paracetamol and citric acid. J. Pharm. Pharmacol. 59, 373-381. (Pubitemid 47050901)
35. Hoppu, P., Hietala, S., Schantz, S., Juppo, A.M., 2009. Rheology and molecular mobility of amorphous blends of citric acid and paracetamol. Eur. J. Pharm. Biopharm. 71, 55-63.
36. Hu, Y., Wang, J., Zhi, Z., Jiang, T., Wang, S., 2011. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J. Colloid. Interface Sci. 363, 410-417.
37. Hüttenrauch, R., Fricke, S., Zielke, P., 1985. Mechanical activation of pharmaceutical systems. Pharm. Res. 2, 302-306. (Pubitemid 16193203)
38. Jackson, C.L., McKenna, G.B., 1996. Vitrification and crystallization of organic liquids confined to nanoscale pores. Chem. Mater. 8, 2128-2137. (Pubitemid 126475402)
39. Janssens, S., Van den Mooter, G., 2009. Review: physical chemistry of solid dispersions. J. Pharm. Pharmacol. 61, 1571-1586.
40. Jayasankar, A., Good, D.J., Rodriguez-Hornedo, N., 2007. Mechanisms by which moisture generates cocrystals. Mol. Pharm. 4, 360-372. (Pubitemid 46983953)
41. Johari, G.P., 1973. Intrinsic mobility of molecular glasses. J. Chem. Phys. 58, 1766-1770.
42. Johari, G.P., Goldstein, M., 1970. Viscous liquids and the glass transition, II. Secondary relaxations in glasses of rigid molecules. J. Chem. Phys. 53, 2372-2388.
43. Karmwar, P., Boetker, J.P., Graeser, K.A., Strachan, C.J., Rantanen, J., Rades, T., 2011a. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin. Eur. J. Pharm. Sci. 44, 341-350.
44. Karmwar, P., Graeser, K., Gordon, K.C., Strachan, C.J., Rades, T., 2011b. Investigation of properties and recrystallization behaviour of amorphous indomethacin samples prepared by different methods. Int. J. Pharm. 417, 94-100.
45. Kaushal, A.M., Bansal, A.K., 2008. Thermodynamic behavior of glassy state of structurally related compounds. Eur. J. Pharm. Biopharm. 69, 1067-1076.
46. Kaushal, A.M., Gupta, P., Bansal, A.K., 2004. Amorphous drug delivery systems: molecular aspects, design and performance. Crit. Rev. Ther. Drug Carrier Syst. 21, 133-193. (Pubitemid 41647581)
47. Kaushal, A.M., Chakraborti, A.K., Bansal, A.K., 2008. FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol. Pharm. 5, 937-945.
48. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 420, 1-10.
49. Kawakami, K., Pikal, M.J., 2005. Calorimetric investigation of the structural relaxation of amorphous materials: evaluating validity of the methodologies. J. Pharm. Sci. 94, 948-965. (Pubitemid 40789961)
50. Kesisoglou, F., Panmai, S., Wu, Y., 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644. (Pubitemid 47285408)
51. Kim, Y., Song, H., 1984. The molecular structure of (+)-6-methoxy- α-methy1-2-naphthaleneacetic acid determined by X-ray method. Arch, Pharmacal. Res. 7, 137-139.
52. Kinnari, P., Mäkilä, E., Heikkilä, T., Salonen, J., Hirvonen, J., Santos, H.A., 2011. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. 414, 148-156.
53. Kistenmacher, T.J., Marsh, R.E., 1972. Crystal and molecular structure of an anti-inflammatory agent, indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2- methylindole-3-acetic acid. J. Am. Chem. Soc. 94, 1340-1345.
54. Konno, T., Kinuno, K., Kataoka, K., 1986. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state, I. Effect of vapor pressure of the medicinals on changes in crystalline properties. Chem. Pharm. Bull. 34, 301-307. (Pubitemid 16135914)
55. Kresge, C.T., Leonowicz, M.E., Roth, W.J., Vartuli, J.C., Beck, J.S., 1992. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359, 710-712. (Pubitemid 23589384)
56. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
57. Limnell, T., Heikkilä, T., Santos, H.A., Sistonen, S., Hellstén, S., Laaksonen, T., Peltonen, L., Kumard, N., Murzin, D.Y., Louhi-Kultanen, M., Salonen, J., Hirvonen, J., Lehto, V.P., 2011. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int. J. Pharm. 416, 242-251.
58. Löbmann, K., Laitinen, R., Grohganz, H., Gordon, K.C., Strachan, C., Rades, T., 2011. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol. Pharm. 8, 1919-1928.
59. Lu, J., Rohani, S., 2009. Polymorphism and crystallization of active pharmaceutical ingredients (APIs). Curr. Med. Chem. 16, 884-905.
60. Löbmann, K., Strachan, C., Grohganz, H., Rades, T., Korhonen, O., Laitinen, R., in press. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur. J. Pharm. Biopharm., http://dx.doi.org/10.1016/j.ejpb.2012.02.004.
61. Löbmann, K., Laitinen, R., Grohganz, H., Gordon, K.C., Strachan, C., Rades, T., submitted for publication. A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin. Int. J. Pharm.
62. Lu, Q., Zografi, G., 1998. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid and PVP. Pharm. Res. 15, 1202-1206. (Pubitemid 28401710)
63. Maheshwari, C., Jayasankar, A., Khan, N.A., Amidon, G.E., Rodriguez-Hornedo, N., 2009. Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants. Cryst. Eng. Comm. 11, 493-500.
64. Mahlin, D., Ponnambalam, S., Höckerfelt, M.H., Christel, A.S., Bergström, C.A.S., 2011. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development. Mol. Pharm. 8, 498-506.
65. Marsac, P.J., Konno, H., Taylor, L.S., 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm. Res. 23, 2306-2316. (Pubitemid 44511511)
66. Marsac, P.J., Li, T., Taylor, L.S., 2009. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm. Res. 26, 139-151.
67. Masuda, T., Yoshihashi, Y., Yonemochi, E., Fujii, K., Uekusa, H., Terada, K., 2012. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. Int. J. Pharm. 422, 160-169.
68. Matsumoto, T., Zografi, G., 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm. Res. 16, 1722-1728. (Pubitemid 29530405)
69. Mellaerts, R., Jammaer, J.A.G., Van Speybroeck, M., Chen, H., Van Humbeeck, J., Augustijns, P., Van den Mooter, G., Martens, J.A., 2008a. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir 24, 8651-8659.
70. Mellaerts, R., Mols, R., Jammaer, J.A.G., Aerts, C.A., Annaert, P., Van Humbeeck, J., Van den Mooter, G., Augustijns, P., Martens, J.A., 2008b. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm. 69, 223-230.
71. Mellaerts, R., Roeffaers, M.B., Houthoofd, K., Van Speybroeck, M., De Cremer, G., Jammaer, J.A., Van den Mooter, G., Augustijns, P., Hofkens, J., Martens, J.A., 2011. Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material. Phys. Chem. Chem. Phys. 21, 2706-2713.
72. Miller, D.P., Lechuga-Ballesteros, D., 2006. Rapid assessment of the structural relaxation behavior of amorphous pharmaceutical solids: effect of residual water on molecular mobility. Pharm. Res. 23, 2291-2305. (Pubitemid 44511510)
73. Miura, H., Kanebako, M., Shirai, H., Nakao, H., Inagia, T., Terada, K., 2011. Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio) phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state 13 C NMR spectroscopy. Int. J. Pharm. 410, 61-67.
74. Miyazaki, T., Yoshioka, S., Aso, Y., Kawanishi, T., 2006. Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature. Int. J. Pharm. 336, 191-195.
75. Newman, A.W., Reutzel-Edens, S.M., Zografi, G., 2008. Characterization of the "hygroscopic" properties of active pharmaceutical ingredients. J. Pharm. Sci. 97, 1047-1059.
76. Ohta, M., Buckton, G., 2005. A study of the differences between two amorphous spray-dried samples of cefditoren pivoxil which exhibited different physical stabilities. Int. J. Pharm. 289, 31-38. (Pubitemid 40093538)
77. Pajula, K., Taskinen, M., Lehto, V.P., Ketolainen, J., Korhonen, O., 2010. Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. Mol. Pharm. 7, 795-804.
78. Patterson, J.E., James, M.B., Forster, A.H., Lancaster, R.W., Butler, J.M., Rades, T., 2005. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 94, 1998-2012. (Pubitemid 41551483)
79. Prestidge, C.A., Barnes, T.J., Lau, C.H., Barnett, C., Loni, A., Canham, L., 2007. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin. Drug Deliv. 4, 101-110. (Pubitemid 46389909)
80. Qi, S., Avalle, P., Saklatvala, R., Craig, D.Q.M., 2008. An investigation into the effects of thermal history on the crystallisation behaviour of amorphous paracetamol. Eur. J. Pharm. Biopharm. 69, 364-371. (Pubitemid 351471777)
81. Qian, K.K., Bogner, R.H., 2011. Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media. Part 1: thermodynamics of spontaneous amorphization. J. Pharm. Sci. 100, 2801-2815.
82. Qian, K.K., Bogner, R.H., 2012. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J. Pharm. Sci. 101, 444-463.
83. Qian, F., Huang, J., Hussain, M.A., 2010. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J. Pharm. Sci. 99, 2941-2947.
84. Riikonen, J., Xu, W., Lehto, V.P., submitted for publication. Mesoporous systems for poorly soluble drugs. Int. J. Pharm.
85. Rowe, R.C., Sheskey, P.J., Fenton, M.E., 2011. Pharmaceutical Excipients. Pharmaceutical Press and American Pharmacists Association, London, UK.
86. Rumondor, A.C., Taylor, L.S., 2010. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol. Pharm. 5, 477-490.
87. Rumondor, A.C.F., Ivanisevic, I., Bates, S., Alonzo, D.E., Taylor, L.S., 2009. Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm. Res. 26, 2523-2534.
88. Salonen, J., Laitinen, L., Kaukonen, A.M., Tuura, J., Björkqvist, M., Heikkilä, T., Vähä-Heikkilä, K., Hirvonen, J., Lehto, V.P., 2005. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J. Control. Release 108, 362-374. (Pubitemid 41608668)
89. Savolainen, M., Heinz, A., Strachan, C., Gordon, K.C., Yliruusi, J., Rades, T., Sandler, N., 2007. Screening for differences in the amorphous state of indomethacin using multivariate visualization. Eur. J. Pharm. Sci. 30, 113-123. (Pubitemid 46149278)
90. Schantz, S., Hoppu, P., Juppo, A.M., 2009. A solid-state NMR study of phase structure, molecular interactions, and mobility in blends of citric acid and paracetamol. J. Pharm. Sci. 98, 1862-1870.
91. Seefeldt, K., Miller, J., Alvarez-Nunez, F., Rodriquez-Hornedo, N., 2007. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy and calorimetry studies. J. Pharm. Sci. 96, 1147-1158. (Pubitemid 46797483)
92. Sekiguchi, K., Obi, N., 1961. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 9, 866-872.
93. Serajuddin, A.T.M., 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59, 603-616. (Pubitemid 47285406)
94. Serajuddin, A.T.M., 1999. Solid dispersion of poorly water-soluble drugs: early promises and recent breakthroughs. J. Pharm. Sci. 88, 1058-1066.
95. Sethia, S., Squillante, E., 2003. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 20, 215-247. (Pubitemid 37237280)
96. Shen, S.C., Ng, W.K., Chia, L., Hu, J., Tan, R.B.H., 2011. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int. J. Pharm. 410, 188-195.
97. Simovic, S., Ghouchi-Eskandar, N., Sinn, A.M., Losic, D., Prestidge, C.A., 2011. Silica materials in drug delivery applications. Curr. Drug Discov. Technol. 8, 269-276.
98. Sing, K.S.W., Everett, D.H., Haul, R.A.W., Moscou, L., Pierotti, R.A., Rouquerol, J., Siemieniewska, T., 1985. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity. Pure Appl. Chem. 54, 603-619.
99. Srinarong, P., de Waard, H., Frijlink, H.W., Hinrichs, W.L.J., 2011. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opin. Drug Deliv. 8, 1121-1140.
100. Van den Mooter, G., Wuyts, M., Blaton, N., Busson, R., Grobet, P., Augustijns, P., Kinget, R., 2001. Physical stabilization of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 12, 261-269.
101. Van Eerdenbrugh, B., Baird, J.A., Taylor, L.S., 2010. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation - classification and comparison with crystallization tendency from undercooled melts. J. Pharm. Sci. 99, 3826-3838.
102. Van Speybroeck, M., Barillaro, V., Thi, T.D., Mellaerts, R., Martens, J., Van Humbeeck, J., Vermant, J., Annaert, P., Van den Mooter, G., Augustijns, J., 2009. J. Pharm. Sci 98, 2648-2658.
103. Vasconcelos, T., Sarmento, B., Costa, P., 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12, 1068-1075. (Pubitemid 350186132)
104. Vishweshwar, P., McMahon, J., Bis, J.A., Zaworotko, M.J., 2006. Pharmaceutical cocrystals. J. Pharm. Sci. 95, 499-516.
105. Vyazovkin, S., Dranca, I., 2005. Physical stability and relaxation of amorphous indomethacin. J. Phys. Chem. B 109, 18637-18644. (Pubitemid 41472062)
106. Vyazovkin, S., Dranca, I., 2006. Probing beta relaxation in pharmaceutically relevant glasses by using DSC. Pharm. Res. 23, 422-428. (Pubitemid 43237872)
107. Wang, F., Hui, H., Barnes, T.J., Barnett, C., Prestidge, C.A., 2010. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. Mol. Pharm. 7, 227-236.
108. Watanabe, T., Wakiyama, N., Usui, F., Ikeda, M., Isobe, T., Senna, M., 2001. Stability of amorphous indomethacin compounded with silica. Int. J. Pharm. 226, 81-91. (Pubitemid 32800785)
109. Watanabe, T., Hasegawa, S., Wakiyama, N., Usui, F., Kusai, A., Isobe, T., Senna, M., 2002. Solid state radical recombination and charge transfer across the boundary between indomethacin and silica under mechanical stress. J. Solid State Chem. 164, 27-33.
110. Yamamura, S., Momose, M., Takahashi, K., Nagatani, S., 1996. Solid-state interaction between cimetidine and naproxen. Drug Stability 50, 173-178. (Pubitemid 27035984)
111. Yamamura, S., Gotoh, H., Sakamoto, Y., Momose, Y., 2000. Physicochemical properties of amorphous precipitates of cimetidine-indomethacin binary system. Eur. J. Pharm. Biopharm. 49, 259-265. (Pubitemid 30229875)
112. Yamamura, S., Gotoh, H., Sakamoto, Y., Momose, Y., 2002. Physicochemical properties of amorphous salt of cimetidine and diflunisal system. Int. J. Pharm. 241, 213-221. (Pubitemid 34718023)
113. Yoshioka, M., Hancock, B.C., Zografi, G., 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83, 1700-1705.
114. Yu, L., 2001. Amorphous pharmaceutical solids; preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48, 27-42. (Pubitemid 32454482)
115. Zhang, F., Aaltonen, J., Tian, F., Saville, D.J., Rades, T., 2009. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur. J. Pharm. Biopharm. 71, 64-70.
116. Zhao, D., Feng, J., Huo, Q., Melosh, N., Fredrickson, G.H., Chmelka, B.F., Stucky, G.D., 1998. Triblock copolymer syntheses of mesoporous silica with periodic 50-300 Å pores. Science 279, 548-552. (Pubitemid 28067280)
117. Zheng, E., Jain, A., Papoutsakis, D., Dannenfelser, R.M., Panicucci, R., Garad, S., 2012. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev. Ind. Pharm. 38, 235-247.
118. Zhou, D., Grant, D.J.W., Zhang, G.G.Z., Law, D., Schmitt, E.A., 2002. Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci. 91, 71-83.
119. Zhou, D., Grant, D.J.W., Zhang, G.G.Z., Law, D., Schmitt, E.A., 2007. A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses. J. Pharm. Sci. 96, 71-83. (Pubitemid 46087340)
120. Zhou, D., Zhang, G.G.Z., Law, D., Grant, D.J.W., Schmitt, E.A., 2008. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol. Pharm. 5, 927-936.